Real-world data reinforce SGLT2 inhibitors as first-line therapy for frail, older adults with heart failure with preserved ...

For patients with diabetes and early-stage pulmonary malignancies, administration of a sodium-glucose cotransporter 2 ...

For patients with diabetes and early-stage pulmonary malignancies, administration of a sodium-glucose cotransporter 2 inhibitor (SGLT2-i) slows nodule growth and reduces the need for surgical ...

Fibrosis occurs when inflammation activates immune cells and fibroblasts to release collagen and cytokines that remodel and ...

A comparative effectiveness study of glucose-lowering drugs finds the GLP-1 receptor agonists most protective against ...

The diabetes drug empagliflozin (Jardiance) and an insulin nasal spray both showed promising effects on memory, brain health ...

Novo Nordisk announced its oral GLP-1 has been approved by the FDA to reduce risk for major adverse cardiovascular events in ...

Novartis reports that Fabhalta® achieved the Phase III APPLAUSE-IgAN primary endpoint, showing slowed kidney-function decline ...

Diuretics serve as essential but symptomatic therapy in heart failure management, functioning primarily as a “bailout ...

A new health concern, Cardiovascular-Kidney-Metabolic Syndrome or CKM, affects nearly ninety percent of adults in the United ...

"We are headed down the road of increasing development and utilization of devices to treat heart failure," Dr. William ...

Semaglutide reduces cardiovascular events by 23% and direct heart disease death risk by 26% compared to dulaglutide in older ...